ZA202301221B - Compositions and methods related to ebola virusvaccines - Google Patents

Compositions and methods related to ebola virusvaccines

Info

Publication number
ZA202301221B
ZA202301221B ZA2023/01221A ZA202301221A ZA202301221B ZA 202301221 B ZA202301221 B ZA 202301221B ZA 2023/01221 A ZA2023/01221 A ZA 2023/01221A ZA 202301221 A ZA202301221 A ZA 202301221A ZA 202301221 B ZA202301221 B ZA 202301221B
Authority
ZA
South Africa
Prior art keywords
compositions
virusvaccines
ebola
ebolavirus
proteins
Prior art date
Application number
ZA2023/01221A
Other languages
English (en)
Inventor
He Linling
Zhu Jiang
Chaudhary Anshul
Wilson Ian
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of ZA202301221B publication Critical patent/ZA202301221B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA2023/01221A 2020-08-10 2023-01-30 Compositions and methods related to ebola virusvaccines ZA202301221B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063063530P 2020-08-10 2020-08-10
PCT/US2021/045178 WO2022035739A2 (en) 2020-08-10 2021-08-09 Compositions and methods related to ebola virusvaccines

Publications (1)

Publication Number Publication Date
ZA202301221B true ZA202301221B (en) 2024-05-30

Family

ID=80114705

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/01221A ZA202301221B (en) 2020-08-10 2023-01-30 Compositions and methods related to ebola virusvaccines

Country Status (10)

Country Link
US (2) US11305004B2 (https=)
EP (1) EP4192500A4 (https=)
JP (1) JP7631502B2 (https=)
CN (1) CN116472278A (https=)
AU (1) AU2021324954A1 (https=)
CA (1) CA3190148A1 (https=)
IL (1) IL300527A (https=)
MX (1) MX2023001433A (https=)
WO (1) WO2022035739A2 (https=)
ZA (1) ZA202301221B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024130061A1 (en) * 2022-12-16 2024-06-20 Cz Biohub Sf, Llc Immunogenic ebolavirus fusion proteins and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211378B2 (en) * 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
GB201502209D0 (en) * 2015-02-10 2015-03-25 Sec Dep For Health The And Chancellor Masters And Scholars Of The University Of Oxford The And Micro Filovirus therapy
WO2016145385A2 (en) 2015-03-11 2016-09-15 Integrated Biotherapeutics, Inc. Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
US11135280B2 (en) * 2016-03-28 2021-10-05 Integrated Biotherapeutics, Inc. Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity
KR20260047644A (ko) * 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도
CN107034225B (zh) * 2017-05-04 2020-01-17 中国人民解放军军事医学科学院生物工程研究所 制备埃博拉病毒糖蛋白与基质蛋白融合突变体的方法
WO2019241483A1 (en) 2018-06-13 2019-12-19 The Scripps Research Institute Nanoparticle vaccines with novel structural components
CA3107083A1 (en) * 2018-08-13 2020-02-20 Janssen Vaccines & Prevention B.V. Stabilized filovirus glycoprotein trimers

Also Published As

Publication number Publication date
WO2022035739A3 (en) 2022-03-24
JP7631502B2 (ja) 2025-02-18
US11872277B2 (en) 2024-01-16
US11305004B2 (en) 2022-04-19
US20220040286A1 (en) 2022-02-10
US20220305109A1 (en) 2022-09-29
CN116472278A (zh) 2023-07-21
IL300527A (en) 2023-04-01
CA3190148A1 (en) 2022-02-17
MX2023001433A (es) 2023-03-06
EP4192500A4 (en) 2025-01-01
WO2022035739A2 (en) 2022-02-17
EP4192500A2 (en) 2023-06-14
AU2021324954A1 (en) 2023-02-23
JP2023537518A (ja) 2023-09-01

Similar Documents

Publication Publication Date Title
MX2021015753A (es) Constructo de arn.
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
MX2026002469A (es) Nuevas moleculas de acido nucleico artificiales
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
PH12020550051A1 (en) Glp-1 compositions and uses thereof
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
WO2020023251A8 (en) Engineered exosomes for medical applications
AU2017260426A1 (en) Engineered nucleases useful for treatment of hemophilia A
ZA202202180B (en) Engineered hcv e2 immunogens and related vaccine compositions
PH12022553153A1 (en) Binding molecules for the treatment of cancer
SA522431748B1 (ar) طرق لإنتاج أرجيناز 1 ناتج بمعاودة الارتباط الجيني بشري واستخداماته
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
ZA202301221B (en) Compositions and methods related to ebola virusvaccines
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
GB2568440A (en) Modified factor H binding protein
WO2021226439A3 (en) Engineered relaxins and methods of use thereof
MX2017012389A (es) Vacuna del virus de la parotiditis recombinante jeryl lynn2.
MX2025008431A (es) Proteinas de fusion fc de il-12
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
JOP20240233A1 (ar) بروتينات cd24 الطافرة واستخداماتها للوقاية من السرطان وعلاجه
SE1750774A1 (en) Novel nucleic acid molecules and their use in therapy
WO2021019235A3 (en) Hantavirus antigenic composition
WO2020022975A3 (en) New pharmaceutical compositions in the treatment of copd